CD8A and metastatic melanoma: Furthermore, PD-1 blockade on IFN-γ– and TNF-producing NY-ESO-1-specific CD8+ T cells isolated from peripheral blood mononuclear cells belonging to patients suffering from metastatic melanoma increases the number of these cells and ameliorates the therapeutic process of these patients [18].